FluidCrystal® injection depot mode of action
Buvidal Administration Video
Upcoming SELECTED congresses in Europe
IOTOD (Improving Outcomes in the Treatment of Opioid Dependence)
18–19 May 2020
More information: Click here for programme details
EUROPAD (European Congress on Heroin Addiction and Related Clinical Problems)
29–31 May 2020
More information: Click here
IOTOD (Improving Outcomes in the Treatment of Opioid Dependence) 2019
13–14 May 2019
More information: Watch webcasts
Albayaty M, Linden M, Olsson H, et al.
Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study.
Adv Ther. 2017;34(2):560–575.
Frost M, Bailey GL, Lintzeris N, et al.
Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder.
Haasen C, Linden M, Tiberg F.
Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
Subst Abuse Treat. 2017;78:22–29.
Lofwall MR, Walsh SL, Nunes EV, et al.
Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial.
JAMA Intern Med. 2018;178(6):764–773.
Walsh SL, Comer SD, Lofwall MR, et al.
Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial.
JAMA Psychiatry. 2017;74(9):894–902.
© 2020 Camurus AB. All rights reserved | INT-BUV-1900007 | Date of preparation: February 2019